Exposure‐Response Relationships for Efficacy and Safety of Risankizumab in Phase 2 and 3 Trials in Psoriasis Patients

Clinical Pharmacology and Therapeutics - United States
doi 10.1002/cpt.1594
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Wiley

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy